Fundraising FoxPolaris Partners — 2015 Investments
12 investments dated 2015 · listed companies and verified rows first · show all
Alector develops therapies targeting neurodegenerative diseases including Alzheimer's, frontotemporal dementia, and Parkinson's disease through protein removal, replacement, and immune cell restoration.
AI & Machine LearningBiotechHealthtechLongevityMedical DevicesSan Francisco, US
Arnon Rosenthal(Ph.D.)inTillman Gerngross(Director)
BoardCarl Gordon(Director)
Board seatTerry McGuire· per SEC Form D
Co-investorsForesite CapitalGV (Google Ventures)Mission Bay CapitalMission BiocapitalMRL Ventures FundSV Health Investors
aTyr is a clinical-stage biotechnology company developing therapies derived from tRNA synthetase biology to treat fibrosis and inflammation, with its lead candidate efzofitimod in clinical trials for interstitial lung disease.
BiotechHealthtechMedical DevicesSan Diego, US
Paul Schimmel(Founder)John D. Mendlein(Executive Officer, Director)David Weiner(Executive Officer)inFrederic Chereau(Executive Officer)
BoardAkkaraju Srinivas(Non-Management Director)
Board seatAmir Nashat· per SEC Form D · $76.3M raise · filed Apr 2015
Co-investorsCardinal PartnersEcoR1 CapitalSofinnova VenturesViking GlobalDomain AssociatesDomain Partners+2 more
Fate Therapeutics develops investigational cellular immunotherapies to treat autoimmune diseases and cancer.
BiotechDigital HealthHealthtechMedical DevicesSan Diego, US
Christian Weyer(Executive Officer, Director)J. Scott Wolchko(Executive Officer)Daniel Shoemaker(Executive Officer)inBahram (Bob) Valamehr(President & Chief Executive Officer)in
BoardJohn Mendlein(Director)
Board seatAmir Nashat· per SEC Form D · $10.3M raise · filed Aug 2016
Co-investorsSanofi VenturesVenrockFidelity InvestmentsOVP Venture Partners
Scholar Rock is a biopharmaceutical company that develops therapies targeting growth factor proteins to treat serious diseases.
BiotechCambridge, US
Nagesh Mahanthappa(Executive Officer, Director)inTimothy Springer(Director)David Hallal(Chief Executive Officer, Chairman and Director)inAkshay Vaishnaw(President of Research & Development and Director)inR. Keith Woods(Chief Operating Officer)inVikas Sinha(Chief Financial Officer)in
Board seatAmir Nashat· per SEC Form D
Co-investorsAisling CapitalARCH Venture PartnersEcoR1 CapitalThe Kraft Group
On-demand alcohol delivery platform providing consumers with a better way to shop for wine and spirits
Sherborn, US
Justin Robinson(Executive Officer)inNicholas Rellas(Executive Officer, Director)James Cory Rellas(Executive Officer)Joseph Grabmeier(Executive Officer)Jacqueline Flug(Executive Officer)Deborah Poole(Director)
Board seatPat Kinsel· per SEC Form D · $34.6M raise · filed Dec 2018
Co-investorsAvenir Growth CapitalEdmonton UnlimitedReynolds and Company Venture PartnersWinklevoss CapitalAvenirSuffolk Equity Partners+1 more
Iora Health was a primary care company focused on value-based care for Medicare-eligible seniors, operating clinics with a team-based model including health coaches.
Digital HealthHealthtechWellness & FitnessSan Francisco, US
RUSHIKA FERNANDOPULLE(Executive Officer, Director)inCHRISTOPHER J. MCKOWN(Executive Officer, Director)DAVID FIELDING(Executive Officer)ALEXANDER PACKARD(Executive Officer)inDAVID JUDGE(Executive Officer)
BoardSTEPHEN KNIGHT(Director)in
Board seatTerry McGuire· per SEC Form D
Co-investors.406 VenturesDag VenturesF-Prime CapitalFlare Capital PartnersGV (Google Ventures)Lifeforce Capital+10 more
Kallyope is a biotechnology company founded by neuroscientists that discovers and develops novel therapeutics targeting neural networks, with a lead candidate in pivotal studies for acute migraine treatment and metabolism programs approaching clinical studies.
BiotechHealthtechNew York City, US
Tom Maniatis(Founder)Nancy Thornberry(Executive Officer, Director)inKenneth Clark(Executive Officer)Charles Zuker(Founder)Richard Axel(Founder)
Board seatTerry McGuire· per SEC Form D · $44M raise · filed Oct 2016
Co-investorsDns CapitalIllumina VenturesLux CapitalThe Column GroupTwo Sigma Ventures
San Diego clinical-stage biopharma developing non-bile acid FXR agonists for liver and gastrointestinal diseases.
BiotechSan Diego, US
Ronald Evans(Director)Trisha Millican(Executive Officer)Ken Song(Executive Officer, Director)
BoardKristina Burow(Director)inRichard Heyman(Director)in
Board seatAmir Nashat· per SEC Form D · $37.8M raise · filed Nov 2016
Co-investorsage1EcoR1 CapitalLAVLifeSci Venture PartnersLilly Asia VenturesNew Enterprise Associates (NEA)+8 more
BiotechCambridge, US
Rick Lundberg(Executive Officer)George P. Vlasuk(Executive Officer, Director)in
BoardJean-Francois Formela(Director)inMarian Nakada(Director)inBrian Gallagher(Director)in
Board seatAlan Crane· per SEC Form D
Co-investorsage1Brace PharmaSanofi VenturesAtlas VentureSR One Capital Management
Repligen provides bioprocessing technologies—including process intensification, tangential flow filtration, chromatography, process analytics, and single-use fluid management—for upstream and downstream biopharmaceutical workflows.
BiotechHardwareMedical DevicesLebanon, US
Tillman Gerngross(Director)Errik Anderson(Director)inWarren Kett(Executive Officer)Jon Sheller(Executive Officer)Kevin Issett(Executive Officer, Director)Kevin Isett(Executive Officer, Director)
Co-investorsOrbiMedSV Health InvestorsBorealis VenturesMithril Capital ManagementNeomed ManagementSands Capital Ventures+1 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.